2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. Ribosomal S6 Kinase (RSK)

Ribosomal S6 Kinase (RSK)

S6K

Ribosomal S6 Kinase (RSK)

Related Products

PDF 0.51 MB

Ribosomal S6 Kinase (RSK) is a family of serine/threonine protein kinases involved in the regulation of cell viability. RSK is phosphorylated in response to mitogens by activation of one or more protein kinase cascades. Phosphorylation of S6 in vivo is catalyzed by (at least) two distinct mitogen-activated S6 kinase families distinguishable by size, the 70 kDa and 90 kDa S6 kinases. Both S6 kinases are activated by serine/threonine phosphorylation.

The p90 ribosomal s6 kinase family (1-4) is a group of highly conserved Ser/Thr kinases that act as downstream effectors of the Ras/Raf/MEK/ERK signaling pathway. They regulate diverse cellular processes, such as cell growth, cell motility, cell survival and cell proliferation. The p70 ribosomal protein S6 kinase, an important member of AGC family, is a kind of multifunctional Ser/Thr kinases, which plays an important role in mTOR signaling cascade. The p70 ribosomal protein S6 kinase is closely associated with diverse cellular processes such as protein synthesis, mRNA processing, glucose homeostasis, cell growth and apoptosis.

Ribosomal S6 Kinase (RSK) Isoform Specific Products:

Ribosomal S6 Kinase (RSK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-52101
    CMK
    		Inhibitor 99.64%
    CMK is a RSK2 kinase inhibitor which exhibits similar potency but less chemical stability compared with FMK.
    CMK
  • HY-16104
    BIX 02565
    		Inhibitor 99.61%
    BIX 02565 is a potent ribosomal S6 kinase 2 (RSK2) inhibitor with IC50 of 1.1 nM.
    BIX 02565
  • HY-101963
    AD80
    		Inhibitor 99.88%
    AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity.
    AD80
  • HY-12059A
    AT7867 dihydrochloride
    		Inhibitor 99.75%
    AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
    AT7867 dihydrochloride
  • HY-12185
    BRD7389
    		Inhibitor 99.75%
    BRD7389 is a specific RSK family kinase inhibitor with IC50s of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells.
    BRD7389
  • HY-14362
    GSK-25
    		Inhibitor 99.68%
    GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively).
    GSK-25
  • HY-132891
    RSK4-IN-1
    		Inhibitor 98.63%
    RSK4-IN-1 is a potent RSK4 inhibitor with a IC50 value of 9.5 nM. RSK4-IN-1 has antitumor activity.
    RSK4-IN-1
  • HY-157133
    TAS0612
    		Inhibitor 98.70%
    TAS0612 is an orally novel inhibitor of RSK、AKT and S6K. TAS0612 has broad-spectrum activity against tumor models via inhibiting cell growth.
    TAS0612
  • HY-52101C
    FMK-MEA
    		Inhibitor 99.40%
    FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.
    FMK-MEA
  • HY-152944
    S6K1-IN-DG2
    		Inhibitor 99.70%
    S6K1-IN-DG2 (Compound 66) is a p70S6K inhibitor (IC50: < 100 nM).
    S6K1-IN-DG2
  • HY-18313
    S6K1-IN-1
    		Inhibitor 99.44%
    S6K-18 is a potent and selective p70S6K1 inhibitor with an IC50 of 52 nM.
    S6K1-IN-1
  • HY-N2357
    Eudesmin
    		Inhibitor 99.96%
    Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.
    Eudesmin
  • HY-132302
    Hu7691
    		Inhibitor
    Hu7691 is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 inhibits tumor growth and enables decrease of cutaneous toxicity in mice.
    Hu7691
  • HY-18507
    AD57
    		Inhibitor 98.08%
    AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity.
    AD57
  • HY-N3628
    Coronarin A
    		Inhibitor ≥98.0%
    Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research.
    Coronarin A
  • HY-12493
    LY-2584702 free base
    		Inhibitor 99.56%
    LY-2584702 free base is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
    LY-2584702 free base
  • HY-101029A
    MBM-55S
    		Inhibitor
    MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice.
    MBM-55S
  • HY-132302A
    Hu7691 free base
    		Inhibitor
    Hu7691 free base is an orally active, selective Akt inhibitor with IC50s of 4.0 nM, 97.5 nM, 28 nM for Akt1, Akt2 and Akt3, respectively. Hu7691 free base inhibits tumor growth and enables decrease of cutaneous toxicity in mice.
    Hu7691 free base
  • HY-W011109
    CKI-7
    		Inhibitor
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases.
    CKI-7
  • HY-112400
    Bisindolylmaleimide V
    		Inhibitor
    Bisindolylmaleimide V is a cell-permeable negative control for protein kinase C inhibition studies with an IC50 value over 100 µM. Bisindolylmaleimide V blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 of 8 µM.
    Bisindolylmaleimide V
Cat. No. Product Name / Synonyms Application Reactivity
Ribosomal S6 Kinase (RSK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.